During Thursday’s trading session, the shares of one of the leading manufacturers of agrochemicals and active pharmaceutical ingredients (APIs) in India surged 14.6 percent to Rs. 648.9 on BSE, after the company received USFDA approval for API Facility located in Dahej, Gujarat.
With a market capitalisation of Rs. 957.5 crores, at 03:00 p.m., the shares of Shivalik Rasayan Limited were trading in the green at Rs. 615, up by nearly 5.6 percent, as against its previous closing price of Rs. 566.3.
What’s the News:
According to the latest regulatory filings with the stock exchanges, the United States Food and Drug Administration (USFDA) approved the API Facility of Shivalik Rasayan Limited, located in the GIDC Industrial Estate, Dahej, Gujarat.
USFDA approval was based on an inspection concluded on 9th April and released Establishment Inspection Report (EIR).
The inspection started on April 1st and closed successfully with 7 observations only on April 9th, 2024.
Financials:
The company reported a significant growth in revenue from operations, experiencing a year-on-year increase of nearly 16 percent, rising from Rs. 64.5 crores in Q1 FY24 to Rs. 74.6 crores in Q1 FY25.
However, during the same period, the company’s net profit decreased from Rs. 6.5 crores to Rs. 3.86 crores, representing a decline of around 40.6 percent YoY.
In terms of return ratios, Shivalik Rasayan reported a return on equity (RoE) of 2.74 percent, and a return on capital employed (RoCE) of 6.08 percent. Additionally, the company’s debt-to-equity ratio stands at 0.15.
About the Company:
Shivalik Rasayan Limited is engaged in the business of manufacturing Agrochemicals & Active Pharma Ingredients (API).
It is the largest producer of Dimethoate Technical and the second-largest producer of Malathion, with a manufacturing facility in Dehradun, Uttarakhand, along with its R&D center in Bhiwadi, Rajasthan, underpins its ongoing advancements.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
